A treatment that targets dysfunctional photoreceptors regardless of the underlying genetic mutation leads to improved ...

Safety signals with faricimab in routine practice, including intraocular inflammation and endophthalmitis, aligned with prior ...

Researchers in the WashU Medicine Department of Ophthalmology & Visual Sciences have discovered key neuroprotective genes ...

An intravitreal ranibizumab injection was able to improve retinal sensitivity and thickness along with improving visual acuity. Branch retinal vein occlusion (BRVO) can affect people aged 40 years and ...

Clearside Biomedical, Inc. has announced that its suprachoroidal injection delivery platform will be prominently featured at the Clinical Trials at the Summit (CTS) Meeting on June 21, 2025, in Las ...

Retinal diseases such as age-related macular degeneration (AMD) and diabetic retinopathy affect millions of people globally, often leading to vision loss with minimal straightforward treatment.

Ashvattha Therapeutics ("Ashvattha"), a clinical-stage company developing a nanomedicine therapeutic that traverses the blood-retinal barrier in areas of inflammation selectively targeting activated ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...

CHICAGO — The number of injections required for the successful treatment of neovascular age-related macular degeneration could be reduced considerably with experimental therapies, new research shows.

The demand for intravitreal vascular endothelial growth factor (VEGF) inhibitor therapy is forecasted to increase by about 50% over the next 5 years in Denmark, due largely to an aging population, a ...